Angiotech and Orthovita Announce Commercial Launch of Vitagel(TM)
Vitagel(TM)Surgical Hemostat is designed for use in cardiovascular, orthopedic, urologic and general surgery indications to control bleeding. Vitagel(TM)differs from other competitors in that it uses autologous (a patient's own) blood as opposed to products from pooled donor blood, thus reducing the risk of transmission of diseases associated with donor blood. Vitagel(TM)has been shown in randomized, controlled studies to reduce blood loss by over 50% during spinal surgeries. CE mark approval for Vitagel(TM)was granted in September 1998. In June 2000, Vitagel(TM)received approval from the United States Food and Drug Administration, or FDA, to market Vitagel(TM)in the U.S.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.